Khan Najat, CEO and President of Recursion Pharmaceuticals ($RXRX), sold shares on the open market three times in the last year, totaling about $845 thousand. The most recent sale occurred on March 9, 2026. These sales rank 5,311th among nearly 12,000 insiders in our database, where the average is $8.6 million across about six transactions per insider. Najat made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 9, 2026 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Khan Najat | CEO and President | S | Class A Common Stock | 28298 | $3.35 | 2,262,085.0000 | 514,895,802 | 1.24% | 0.01% |
| Feb. 17, 2026 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Khan Najat | CEO and President | F | Class A Common Stock | 14280 | $3.49 | 2,290,383.0000 | 514,895,802 | 0.62% | 0.00% |
| Feb. 6, 2026 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Khan Najat | CEO and President | F | Class A Common Stock | 10364 | $3.98 | 2,304,663.0000 | 514,895,802 | 0.45% | 0.00% |
| Feb. 6, 2026 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Khan Najat | CEO and President | A | Class A Common Stock | 30346 | $0.00 | 2,315,027.0000 | 514,895,802 | 1.33% | 0.01% |
| Feb. 6, 2026 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Khan Najat | CEO and President | A | Class A Common Stock | 1673546 | $0.00 | 2,284,681.0000 | 514,895,802 | 273.84% | 0.33% |
| Dec. 22, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Khan Najat | Chief R&D Commercial Officer | S | Class A Common Stock | 124403 | $4.41 | 611,135.0000 | 514,895,802 | 16.91% | 0.02% |
| Nov. 17, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Khan Najat | Chief R&D Commercial Officer | F | Class A Common Stock | 17584 | $4.14 | 735,538.0000 | 514,895,802 | 2.33% | 0.00% |
| Nov. 5, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Khan Najat | Chief R&D Commercial Officer | A | Class A Common Stock | 84925 | $0.00 | 753,122.0000 | 514,895,802 | 12.71% | 0.02% |
| Nov. 5, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Khan Najat | Chief R&D Commercial Officer | A | Stock Option (Right to Buy) | 169851 | $0.00 | 169,851.0000 | 514,895,802 | 9999.99% | 0.03% |
| Aug. 15, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Khan Najat | Chief R&D Commercial Officer | F | Class A Common Stock | 3789 | $5.64 | 704,796.0000 | 395,072,094 | 0.53% | 0.00% |
| Aug. 18, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Khan Najat | Chief R&D Commercial Officer | S | Class A Common Stock | 36599 | $5.52 | 668,197.0000 | 395,072,094 | 5.19% | 0.01% |
| May 15, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Khan Najat | Chief R&D Commercial Officer | F | Class A Common Stock | 3796 | $4.25 | 708,585.0000 | 395,072,094 | 0.53% | 0.00% |
| Feb. 3, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Khan Najat | Chief R&D Commercial Officer | A | Class A Common Stock | 210113 | $0.00 | 707,085.0000 | 395,072,094 | 42.28% | 0.05% |
| Feb. 3, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Khan Najat | Chief R&D Commercial Officer | F | Class A Common Stock | 2753 | $7.25 | 712,381.0000 | 395,072,094 | 0.38% | 0.00% |
| Feb. 3, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Khan Najat | Chief R&D Commercial Officer | A | Stock Option (Right to Buy) | 420226 | $0.00 | 1,414,170.0000 | 395,072,094 | 42.28% | 0.11% |
| Feb. 3, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Khan Najat | Chief R&D Commercial Officer | A | Class A Common Stock | 8049 | $0.00 | 715,134.0000 | 395,072,094 | 1.14% | 0.00% |
| Aug. 1, 2024 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Khan Najat | Chief R&D Commercial Officer | A | Class A Common Stock | 496972 | $0.00 | 496,972.0000 | 0 | 9999.99% | 0.00% |
| Aug. 1, 2024 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Khan Najat | Chief R&D Commercial Officer | A | Stock Option (Right to Buy) | 993944 | $0.00 | 993,944.0000 | 0 | 9999.99% | 0.00% |